Mark Malesker, PharmD, discusses the clinical evidence, drug interaction risks, and formulary challenges surrounding cannabinoid use for sleep disorders.
Objective: Health care resource utilization (HCRU) and cost among Medicaid patients with serious mental illness (SMI) were ...
AJMC: 64% of patients who responded to pCR skipped traditional chemotherapy entirely, and 97% avoided anthracyclines. For patients and oncologists, what does that mean in practice, and how do you ...
After decades of neglect, malnutrition-related diabetes, or type 5, is finally getting the research, recognition, and ...
In this episode titled, 'Understanding Neuroendocrine Carcinomas: Definitions, Types, and Clinical Presentation,' Ryan Haumschil ...
New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal. In this installment of this series, ‘The Future of Factor XIa ...